23Andme Holding Correlations
ME Stock | USD 3.35 0.02 0.60% |
The current 90-days correlation between 23Andme Holding and Twist Bioscience Corp is 0.36 (i.e., Weak diversification). The correlation of 23Andme Holding is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
23Andme Holding Correlation With Market
Significant diversification
The correlation between 23Andme Holding Co and DJI is 0.05 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding 23Andme Holding Co and DJI in the same portfolio, assuming nothing else is changed.
23Andme |
Moving together with 23Andme Stock
0.8 | VALN | Valneva SE ADR | PairCorr |
0.76 | ERNA | Eterna Therapeutics | PairCorr |
0.76 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.82 | LLY | Eli Lilly | PairCorr |
0.89 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.85 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
0.71 | SXTPW | 60 Degrees Pharmaceu | PairCorr |
0.85 | MRVI | Maravai Lifesciences | PairCorr |
0.92 | REGN | Regeneron Pharmaceuticals | PairCorr |
0.66 | ABBV | AbbVie Inc | PairCorr |
0.87 | AKAN | Akanda Corp | PairCorr |
0.82 | AMGN | Amgen Inc | PairCorr |
0.76 | ANRO | Alto Neuroscience, | PairCorr |
0.67 | APGE | Apogee Therapeutics, | PairCorr |
0.76 | ARDX | Ardelyx | PairCorr |
Moving against 23Andme Stock
0.83 | BMY | Bristol Myers Squibb | PairCorr |
0.77 | GILD | Gilead Sciences | PairCorr |
0.71 | ESPR | Esperion Therapeutics | PairCorr |
0.57 | DYAI | Dyadic International | PairCorr |
0.74 | MNMD | Mind Medicine | PairCorr |
0.65 | ABCL | Abcellera Biologics | PairCorr |
0.56 | MOLN | Molecular Partners | PairCorr |
0.89 | TARS | Tarsus Pharmaceuticals | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between 23Andme Stock performing well and 23Andme Holding Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze 23Andme Holding's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
IDXX | 1.19 | (0.26) | 0.00 | (0.18) | 0.00 | 2.26 | 12.05 | |||
TWST | 2.92 | 0.30 | 0.07 | 0.91 | 3.31 | 6.77 | 17.25 | |||
GH | 2.78 | 0.35 | 0.16 | 0.27 | 2.47 | 7.53 | 17.48 | |||
DMTK | 13.43 | 0.12 | 0.01 | 0.21 | 19.54 | 27.66 | 119.09 | |||
A | 1.22 | (0.01) | (0.05) | 0.08 | 1.47 | 2.71 | 9.02 | |||
TMO | 0.95 | (0.31) | 0.00 | (0.45) | 0.00 | 1.66 | 7.00 | |||
DHR | 1.00 | (0.27) | 0.00 | (0.45) | 0.00 | 1.47 | 7.35 | |||
BIOC | 6.16 | (2.39) | 0.00 | 2.45 | 0.00 | 9.24 | 66.54 |
23Andme Holding Corporate Management
Anne Wojcicki | CEO, CoFounder | Profile | |
Joseph Selsavage | Interim Officer | Profile | |
Katie Watson | Vice Communications | Profile | |
MB ChB | Executive Officer | Profile | |
Wade Walke | VP Relations | Profile | |
Jennifer Low | Head Development | Profile | |
JD Esq | Chief Secretary | Profile |